HOME > TOP STORIES

TOP STORIES

REGULATORY New Stable Supply Panel Wants to Define “Key Drugs” by This Summer

March 30, 2020
REGULATORY PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost

March 30, 2020
REGULATORY Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate

March 27, 2020
REGULATORY Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More

March 26, 2020
REGULATORY Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis

March 25, 2020
BUSINESS Novartis Japan to Shed Oncology Staffers amid Overall Downscaling

March 24, 2020
ACADEMIA Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir

March 24, 2020
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now

March 24, 2020
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official

March 23, 2020
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually

March 19, 2020
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers

March 19, 2020
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review

March 18, 2020
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan

March 17, 2020
ORGANIZATION Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA

March 16, 2020
BUSINESS Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue

March 13, 2020
COMMENTARY Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?

March 12, 2020
BUSINESS Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus

March 11, 2020
REGULATORY Japan Cabinet OKs Bill to Allow Govt to Declare Emergency over Coronavirus

March 11, 2020
BUSINESS Japan’s 2020 Price Revision Hits Major Drugs with Double-Digit Slashes: Top 5 Product Survey

March 10, 2020
BUSINESS Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll

March 9, 2020

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…